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Introduction
Topic
• The chosen topic for the poster
project was malignant
melanoma.
• The incidence of malignant
melanoma has continued to
increase over the years and it
has become one of the top five
most common cancers in the
United States (Kauffmann &
Chen, 2014).
• The incidence of melanoma has
also increased worldwide
( Azoury & Lange, 2014).
• 5th and 7th most common cancer
in men and women respectively
(Azoury & Lange 2014).

Explanation for Topic Choice
• The appeal in the topic derived
from diagnosis of multiple family
members, leading to an interest
in enhancing personal
knowledge.
• Goal to further educate others
about malignant melanoma, its
origin, risk factors, prevention
and treatment.

Signs & Symptoms
• A new abnormal looking
growth or an existing mole that
undergoes changes should be
evaluated
Ø Early signs of melanoma are
described by the mnemonic
“ABCDE” (Kauffman & Chen,
2014, p. 964 & American
Cancer Society, 2018)
o A = asymmetry and refers to
one half of the mole or growth
not matching the other half.
o B = border and refers to
irregular edges.
o C = color and refers to the color
being inconsistent and may
include different shades or
patches
o D = Diameter and refers to the
mole being greater than 6mm
across (although melanomas
can be smaller than 6mm)
o E = Evolution or Elevation
referring to the mole changing
in size, shape or color or
becoming elevated.
• According to the American
Cancer Society other signs of
potential melanoma are
Ø “A sore that does not heal”
Ø “Spread of pigment from the
boarder of a spot into
surrounding skin”
Ø “Redness or new swelling
beyond the border of the mole”
Ø “Change in sensation, such as
itchiness, tenderness or pain”
Ø “Change in the surface of a
mole - scaliness, oozing,
bleeding, or the appearance of
a lump or bump”

Figure 1. Mnemonic “ABCDE”

(Kauffmann & Chen, 2014, p. 964)

Risk factors for melanoma

(Azoury & Lange, 2014, p.949)
• Acquired & Environmental
Ø Ultraviolet light
Ø Cancer history
o Significantly increases risk regardless
of the type of skin cancer
Ø Immunosuppression
Ø Socioeconomic Status
Ø Obesity
Ø Occupation/Exposure
• Demographics and Phenotypes
Ø Race - Caucasian
Ø Male
Ø Age > 65
Ø Light hair, light eyes, fair skin
Ø Multiple atypical Nevi
• Familial, Genetics & Epigenetics
Ø microRNA
Ø High, low risk Allele
Ø MITF, other mutations

Pathophysiology
Underlying
• Melanin is cells of the skin from which
pigment is generated and it is
synthesized by melanocytes (McCance
& Huether, 2019, p.85.
• Melanoma is an aggressive malignancy
borne of melanocytes (Hawryluk &
Tsao, 2014, p.2).
• The pathophysiology sequence leading
to melanoma is not well defined and the
molecular trigger for transformation to
melanoma is unknown. However,
certain genes and signaling pathways
have been discovered to have a role in
the pathophysiology of melanoma
(Hawryluk and Tsao, 2014, p.2).
Significance
• Melanoma is a “molecularly
heterogeneous disease” and research
has identified many genetic alterations.
Identifying genetic mutations can
provide a positive clinical impact on
patient care (Hawryluk and Tsao, 2014,
p.1).

• Germline melanoma
ØCDKN2A (Hawryluk & Tsao, 2014)
o Cyclin-dependent kinase inhibitor 2A
encode tumor suppressor proteins which
function in cell cycle arrest.
o High penetrance gene
o 70% increased risk of melanoma for
those who carry the mutation
o Most common mutation in hereditary
melanoma. “Familial melanoma in the
presence of multiple atypical nevi should
raise suspicion for a germline CDKN2A
mutation (Soura et al. 2015, p. 395)
ØBRAF (Hawryluk & Tsao, 2014)
o Associated with intense intermittent UV
radiation exposure
o Most often found in the younger
population
o More than 60% of cutaneous melanoma
have BRAF mutation
o In initial studies tumor regression was
achieved with selective inhibition of
BRAF.

Figure 2.

Implications for
Nursing Care
• The nurse practitioner (NP)
has the ability to help patients
prevent, detect, and treat
malignant melanoma.
• Educating patients on
prevention strategies can help
decrease their risk of
melanoma, such as
Ø Wearing sunscreen and
protective clothing, limiting
exposure time in the sun,
avoiding tanning beds, and
checking and monitoring
moles and growths on the skin.
• Following the mnemonic
“ABCDE” can help the patient
as well as the provider spot a
potential melanoma.
• Should a suspicious lesion be
noted it should be biopsied
and if found to be melanoma,
staged appropriately according
to the depth of the tumor
(Breslow thickness test) and
the mitotic rate (Mrazek &
Chao, 2014)
• It is also important to obtain a
family history of melanoma to
determine a possible genetic
link.

Conclusion
With the incidence of melanoma
continuing to increase it is important to
obtain a complete history and physical.
Family and self history is of great
importance. Any suspicious lesions
should be biopsied and staged in order
to allow the patient to have the best
optimal outcomes.
“A molecular map of melanoma. Heritable loci with risk alleles or single-nucleotide
polymorphisms are shown in italics with asterisks (e.g., CDKN2A*). Red and gray colors indicate
somatic alterations that result in gain of function (i.e., oncogenes such as BRAF) or loss of
function (i.e., tumor-suppressor genes such as PTEN), respectively. (Figure based on modified
data from Tsao et al. 2012)” (Hawryluk & Tsao, 2014, p. 4)
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